Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q2 2017 · 10-Q
Revenue$8.67M$8.67M+16.9% vs Q2 2016 Net Income-$5.16M-$5.16MN/M vs Q2 2016 EPS Diluted-$0.32-$0.32— vs Q2 2016 Operating Income-$1,680,871N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,549,571N/M Margins · derivedOperating margin-19.4%−18.0 pt vs Q2 2016
Net margin-59.5%−58.9 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 9, 2017 · 40 d after period end